SAN MATEO, California—Bioelectric medicine provider Cala Health announced that its Cala kIQ System has been named "Best New Neurology Technology Solution" as part of the 2026 MedTech Breakthrough Awards. Cala's at-home neurology technology platform helps patients struggling with essential tremor (ET) to access and receive care.
The awards honor excellence and recognize innovation and success in various health and medical technology categories. This year's program attracted more than 5,000 nominations from around the globe. The company is part of a group of 2026 winners that includes Noom, Boston Scientific, Teladoc, Medtronic, DocGo, Zimmer Biomet, CVS Health, Lyra Health, Elsevier, Medidata, IQVIA, Thermo Fisher Scientific, PointClickCare, Canon Medical Systems and Alcon/Novartis, among others.
"Being named the Best New Neurology Technology Solution by the MedTech Breakthrough Awards is a meaningful validation of the work our entire team has poured into making Cala TAPS Therapy a reality for patients living with essential tremor," said Deanna Harshbarger, CEO of Cala Health. "For too long, people with ET have had limited options that fit into their daily lives. We set out to change that with a non-invasive, wearable therapy they can use at home. This recognition reflects not just our technology, but our commitment to expanding access. We're proud of how far we've come, and even more energized about what's ahead."
The Cala kIQ system delivers TAPS Therapy through a noninvasive wrist-worn wearable neuromodulation device, which is physician-prescribed and aids in the temporary relief of hand tremors in adults with ET. The disease affects over 7 million Americans, causing uncontrollable hand and arm shaking that disrupts daily activities, and pre-existing treatment options are often insufficient or require invasive surgical options. The Cala kIQ System bridges this treatment gap and eases symptoms in the treated hand following stimulation.